Nitrosative stress and pharmacological modulation of heart failure

Trends in Pharmacological Sciences

Volumn 26, Issue 6, 2005, Pages 302-310

  Pacher, Pal ^a   Schulz, Richard ^b   Liaudet, Lucas ^c   Szabó, Csaba ^d,e,f  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^f INOTEK CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 MERCAPTOETHYL)GUANIDINE; 1,11B DIHYDRO[2H]BENZOPYRANO[4,3,2 DE]ISOQUINOLIN 3 ONE; 3 AMINOBENZAMIDE; 5 AMINOISOQUINOLINONE; 5,10,15,20 TETRAKIS(4 SULFONATOPHENYL)PORPHYRINATOIRON; ALLOPURINOL; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIBIOTIC AGENT; ANTIOXIDANT; APOCYNIN; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DOXYCYCLINE; FP 15; GPI 6150; GUANIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INO 1001; INSULIN; IRON CHLORIDE TETRAKIS 2 (TRIETHYLENE GLYCOL MONOMETHYL ETHER)PYRIDYLPORPHYRIN; ISOQUINOLINE DERIVATIVE; KETONE DERIVATIVE; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; O (2 HYDROXY 3 PIPERIDINOPROPYL)NICOTINIC AMIDOXIME; ORAL ANTIDIABETIC AGENT; OXIPURINOL; PEROXYNITRITE; PORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; TIRON; UBIDECARENONE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ENZYME ACTIVATION; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PEROXYNITROUS ACID; POLY(ADP-RIBOSE) POLYMERASES;

EID: 19544392527     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.04.003     Document Type: Review

References (80)

1. R. Ferrari Oxidative stress during myocardial ischaemia and heart failure Curr. Pharm. Des. 10 2004 1699 1711
2. C. Heymes Increased myocardial NADPH oxidase activity in human heart failure J. Am. Coll. Cardiol. 41 2003 2164 2171
3. C.E. Berry, and J.M. Hare Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications J. Physiol. 555 2004 589 606
4. J.M. Hare, and J.S. Stamler NO/redox disequilibrium in the failing heart and cardiovascular system J. Clin. Invest. 115 2005 509 517
5. P.B. Massion Nitric oxide and cardiac function: ten years after, and continuing Circ. Res. 93 2003 388 398
6. W.J. Paulus, and J.G. Bronzwaer Nitric oxide's role in the heart: control of beating or breathing? Am. J. Physiol. Heart Circ. Physiol. 287 2004 H8 H13
7. H. Rubbo Nitric oxide regulation of superoxide and peroxynitrite- dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives J. Biol. Chem. 269 1994 26066 26075
8. C. Szabo Multiple pathways of peroxynitrite cytotoxicity Toxicol. Lett. 140-141 2003 105 112
9. I.V. Turko, and F. Murad Protein nitration in cardiovascular diseases Pharmacol. Rev. 54 2002 619 634
10. M.J. Mihm Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure Cardiovasc. Res. 49 2001 798 807
11. I.N. Mungrue Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death J. Clin. Invest. 109 2002 735 743
12. O. Gealekman Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure Circulation 105 2002 236 243
13. T. Damy Increased neuronal nitric oxide synthase-derived NO production in the failing human heart Lancet 363 2004 1365 1367
14. P. Ferdinandy, and R. Schulz Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning Br. J. Pharmacol. 138 2003 532 543
15. P. Pacher Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction Circulation 107 2003 896 904
16. P. Bai Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity Oncol. Rep. 11 2004 505 509
17. A.A. Chaves Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues Cardiovasc. Res. 60 2003 108 118
18. A. Ceriello Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat Diabetes 51 2002 1076 1082
19. M.J. Mihm, and J.A. Bauer Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase Biochimie 84 2002 1013 1019
20. M.J. Mihm Effects of peroxynitrite on isolated cardiac trabeculae: selective impact on myofibrillar energetic controllers Biochimie 85 2003 587 596
21. P. Pacher Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure J. Am. Coll. Cardiol. 40 2002 1006 1016
22. W.H. Lee Influence of peroxynitrite on energy metabolism and cardiac function in a rat ischemia-reperfusion model Am. J. Physiol. Heart Circ. Physiol. 285 2003 H1385 H1395
23. F.H. Khadour Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats Am. J. Physiol. Heart Circ. Physiol. 283 2002 H1108 H1115
24. M. Iqbal Time course of nitric oxide, peroxynitrite and antioxidants in the endotoxemic heart Crit. Care Med. 30 2002 1291 1296
25. N. Keira Lethal effect of cytokine-induced nitric oxide and peroxynitrite on cultured rat cardiac myocytes J. Mol. Cell. Cardiol. 34 2002 583 596
26. C.Q. Gao Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction Cardiovasc. Res. 57 2003 426 433
27. C.S.R. Baker Repetitive myocardial stunning in pigs is associated with an increased formation of reactive nitrogen species Heart 87 2002 77 78
28. Y. Hayashi Leukocyte-depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium-derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 minutes J. Thorac. Cardiovasc. Surg. 126 2003 1813 1821
29. U. Mehlhorn Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia J. Thorac. Cardiovasc. Surg. 125 2003 178 183
30. C.S. Baker Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium Basic Res. Cardiol. 97 2002 409 415
31. A.A. Miller Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure Br. J. Pharmacol. 131 2000 29 36
32. P.C. Colombo Endothelial cell activation in patients with decompensated heart failure Circulation 111 2005 58 62
33. T. Okamoto Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation J. Biol. Chem. 276 2001 29596 29602
34. M.M. Lalu Peroxynitrite in myocardial ischemia-reperfusion injury Heart Fail. Rev. 7 2002 359 369
35. L. Virag, and C. Szabo The therapeutic potential of poly(ADP-ribose) polymerase inhibitors Pharmacol. Rev. 54 2002 375 429
36. F.G. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ. Res. 90 2002 520 530
37. D.A. Siwik, and W.S. Colucci Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium Heart Fail. Rev. 9 2004 43 51
38. P.Y. Cheung Matrix etalloproteinase-2 contributes to ischemia-reperfusion injury in the heart Circulation 101 2000 1833 1839
39. W. Wang Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2 Cardiovasc. Res. 53 2002 165 174
40. W. Wang Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury Circulation 106 2002 1543 1549
41. J.T. Peterson Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure Circulation 103 2001 2303 2309
42. A. Ducharme Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J. Clin. Invest. 106 2000 55 62
43. M.K. King Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure Circ. Res. 92 2003 177 185
44. F.G. Spinale A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
45. M.M. Lalu Ischemia-reperfusion injury activates matrix metalloproteinases in the human heart Eur. Heart J. 26 2005 27 35
46. S. Blankenberg Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
47. J.C. Docherty An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart Br. J. Pharmacol. 127 1999 1518 1524
48. G. Szabo Poly(ADP-ribose) polymerase activation in the reperfused myocardium Cardiovasc. Res. 61 2004 471 480
49. J.B. Pillai increased expression of poly (ADP) ribose polymerase-1 contributes to caspase-independent myocyte cell death during heart failure Am. J. Physiol. Heart Circ. Physiol. 288 2005 H486 H496
50. B. Zingarelli Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury Mol. Med. 9 2003 143 153
51. B. Zingarelli Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1 Am. J. Physiol. Heart Circ. Physiol. 286 2004 H1408 H1415
52. P. Pacher Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure J. Pharmacol. Exp. Ther. 300 2002 862 867
53. C.Y. Xiao Poly(ADP-ribose) polymerase promotes cardiac remodeling, contractile failure and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure J. Pharmacol. Exp. Ther. 312 2005 891 898
54. P. Pacher The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes Diabetes 51 2002 514 521
55. C. Szabo Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst Mol. Med. 8 2002 571 580
56. C.Y. Xiao Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor J. Pharmacol. Exp. Ther. 310 2004 498 504
57. P. Pacher Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents Biochem. Pharmacol. 64 2002 1785 1791
58. C. Szabo Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation Mol. Med. 10 2004 28 35
59. C. Fiorillo Poly(ADP-ribose) polymerase activation and cell injury in the course of rat heart heterotopic transplantation Free Radic. Res. 36 2002 79 87
60. C. Fiorillo Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation Free Radic. Res. 37 2003 331 339
61. G. Szabo Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation Circ. Res. 90 2002 100 106
62. P. Pacher A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging J. Pharmacol. Exp. Ther. 311 2004 485 491
63. S. Lancel Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats J. Am. Coll. Cardiol. 43 2004 2348 2358
64. C. Di Filippo M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart Eur. J. Pharmacol. 497 2004 65 74
65. G. Szabo Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest J. Thorac. Cardiovasc. Surg. 126 2003 651 658
66. G. Szabo Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg. 25 2004 825 832
67. G. Szabo INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation Shock 21 2004 426 432
68. C. Bianchi A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs Ann. Thorac. Surg. 74 2002 1201 1207
69. O. Szenczi Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure Biochem. Pharmacol. 69 2005 725 732
70. S.K. Wattanapitayakul Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders FASEB J. 14 2000 271 278
71. A.G. Minchenko Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation FASEB J. 17 2003 1514 1516
72. K. Murakami Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts Hypertension 40 2002 251 255
73. T. Takayama Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor Circ. J. 68 2004 1067 1075
74. P. Ferdinandy Peroxynitrite is a major contributor to cytokine-induced contractile failure Circ. Res. 87 2000 241 247
75. P. Pacher Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies Curr. Med. Chem. 12 2005 267 275
76. F.J. Villarreal Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling Circulation 108 2003 1487 1492
77. T.M. Camp Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats J. Heart Lung Transplant. 23 2004 729 736
78. D.L. Brown Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial Arterioscler. Thromb. Vasc. Biol. 24 2004 733 738
79. G.J. Southan, and C. Szabo Poly(ADP-ribose) polymerase inhibitors Curr. Med. Chem. 10 2003 321 340
80. A. Ceriello New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy Diabetes Care 26 2003 1589 1596